Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial

PURPOSE: This prospective study evaluates whether rituximab is a safe and potentially effective treatment for nonparaneoplastic autoimmune retinopathy (npAIR). MATERIALS AND METHODS: Five npAIR patients were enrolled in a Phase I/II, prospective, nonrandomized, open-label, single-center study. All p...

Descripción completa

Detalles Bibliográficos
Autores principales: Armbrust, Karen R., Fox, Austin R., Jeffrey, Brett G., Sherry, Patti, Sen, H. Nida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7971443/
https://www.ncbi.nlm.nih.gov/pubmed/33767957
http://dx.doi.org/10.4103/tjo.tjo_32_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7971443/
https://www.ncbi.nlm.nih.gov/pubmed/33767957
http://dx.doi.org/10.4103/tjo.tjo_32_20

Ejemplares similares